Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer

被引:26
|
作者
Saito, Satoshi [1 ]
Abe, Takanori [1 ]
Kobayashi, Nao [1 ]
Aoshika, Tomomi [1 ]
Ryuno, Yasuhiro [1 ]
Igari, Mitsunobu [1 ]
Hirai, Ryuta [1 ]
Kumazaki, Yu [1 ]
Miura, Yu [2 ]
Kaira, Kyoichi [2 ]
Kagamu, Hiroshi [2 ]
Noda, Shin-ei [1 ]
Kato, Shingo [1 ]
机构
[1] Saitama Med Univ, Dept Radiat Oncol, Int Med Ctr, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Saitama Med Univ, Dept Resp Med, Int Med Ctr, Hidaka, Japan
关键词
Radiation pneumonitis; Dose-volume parameters; Durvalumab; Lung cancer; PHASE-III; CHEMORADIATION; CHEMOTHERAPY; RADIOTHERAPY; CISPLATIN;
D O I
10.1016/j.ctro.2020.05.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: We investigated the incidence and dose-volume relationships of radiation pneumonitis (RP) after concurrent chemoradiotherapy (CCRT) followed by durvalumab for locally advanced non-small-cell lung cancer (LA-NSCLC). Materials and methods: We retrospectively analyzed records of 36 patients with LA-NSCLC who underwent CCRT followed by durvalumab. Incidence of RP was analyzed for correlations with clinical factors and dose-volume parameters of lung in radiotherapy. Results: All patients received 60 Gy in 30 fractions of radiotherapy with concurrent chemotherapy. Over a median follow-up period of 7 months, incidence of grade >= 2 RP was 36% (including grade 3 RP: 5% and grade 5 RP: 3%). Age, sex, Brinkman index, and blood test results did not significantly differ between patients with grade >= 2 RP and grade >= 1 RP. Dose-volume parameters (lung volumes that received 5 Gy, 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, and mean lung dose) were significantly higher among patients with grade >= 2 RP compared with patients with grade >= 1 RP. Conclusion: Incidence of grade >= 2 RP was 36% after CCRT followed by durvalumab for LA-NSCLC, but did not significantly differ from those of patients treated with CCRT alone. Lung dose-volume parameters were significantly correlated with RP. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
引用
收藏
页码:85 / 88
页数:4
相关论文
共 50 条
  • [31] Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer
    Voong, Khinh Ranh
    Naidoo, Jarushka
    LUNG CANCER, 2020, 150 : 249 - 251
  • [32] Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
    Diamond, Brett H.
    Belani, Neel
    Masel, Rebecca
    DeCarli, Kathryn
    DiPetrillo, Thomas
    Hepel, Jaroslaw T.
    Azzoli, Christopher G.
    Khurshid, Humera
    Abbas, Abbas
    Koffer, Paul P.
    ADVANCES IN RADIATION ONCOLOGY, 2023, 8 (02)
  • [33] Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer
    Kusumoto, Sojiro
    Hirose, Takashi
    Fukayama, Motoko
    Kataoka, Daisuke
    Hamada, Kenji
    Sugiyama, Tomohide
    Shirai, Takao
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Kadokura, Mitsutaka
    Adachi, Mitsuru
    ONCOLOGY REPORTS, 2009, 22 (05) : 1157 - 1162
  • [34] Consolidation Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiotherapy
    Basal, F.
    Aslan, F.
    Zengin, G.
    Demirci, U.
    Oksuzoglu, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S853 - S853
  • [35] Concurrent chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer
    Song, X
    Gallant, V
    Laurie, S
    Nicholas, G
    Reaume, N
    MacRae, R
    Agboola, O
    Perry, G
    Lochrin, C
    Goss, G
    LUNG CANCER, 2005, 49 : S174 - S175
  • [36] Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab
    Fukui, Tomoya
    Hosotani, Shinji
    Soda, Itaru
    Ozawa, Takahiro
    Kusuhara, Seiichiro
    Kakegawa, Mikiko I.
    Kasajima, Masashi
    Hiyoshi, Yasuhiro
    Igawa, Satoshi
    Yokoba, Masanori
    Mitsufuji, Hisashi
    Kubota, Masaru
    Katagiri, Masato
    Sasaki, Jiichiro
    Ishiyama, Hiromichi
    Naoki, Katsuhiko
    THORACIC CANCER, 2020, 11 (04) : 1005 - 1014
  • [37] Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer
    Park, Young Hee
    Kim, Jae-Sung
    RADIATION ONCOLOGY JOURNAL, 2013, 31 (01): : 34 - 40
  • [38] Primary surgery followed by chemotherapy versus definitive concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
    Kiladze, I.
    Kuchava, V.
    Joxadze, N.
    Katselashvili, L.
    Melkadze, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S67 - S67
  • [39] Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer
    Byrne, MJ
    Phillips, M
    Powell, A
    Cameron, F
    Joseph, D
    Spry, N
    Dewar, J
    Van Hazel, G
    Buck, M
    Lund, H
    De Melker, Y
    Newman, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (06) : 336 - 342
  • [40] Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer
    Kashihara, Tairo
    Nakayama, Yuko
    Okuma, Kae
    Takahashi, Ayaka
    Kaneda, Tomoya
    Katagiri, Mika
    Nakayama, Hiroki
    Kubo, Yuko
    Ito, Kimiteru
    Nakamura, Satoshi
    Takahashi, Kana
    Inaba, Koji
    Murakami, Naoya
    Saito, Tetsuo
    Okamoto, Hiroyuki
    Itami, Jun
    Kusumoto, Masahiko
    Ohe, Yuichiro
    Igaki, Hiroshi
    RADIOTHERAPY AND ONCOLOGY, 2023, 180